Revance Therapeutics Inc. ($RVNC) reported that it has completed patient enrollment in two pivotal trials of the company’s SAKURA Phase 3 program for its investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of moderate to severe glabellar lines in adults. The company’s Phase 3 program is comprised of two pivotal trials evaluating the efficacy, safety and duration of RT002, as well as a long-term safety trial. It will continue to enroll patients for long-term safety trial.
Vermillion ($VRML) announced that its associate company ASPiRA LABs has attained out-of-state provider status with Medi-Cal, California's Medicaid program, for OVA1®/Multivariate Index Assay. With this development, OVA1 is now available to over 12 million Medi-Cal beneficiaries, representing approximately a third of the covered lives in California.